Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Mirochnick

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
AIDS (London, England)|April 10, 1999
A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006)P Musoke, L A Guay, D Bagenda, et al.
HIV Medicine|March 28, 2008
Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokineticsE V Capparelli, F Aweeka, J Hitti, et al.
Lancet (London, England)|September 15, 1999
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trialL A Guay, P Musoke, T Fleming, et al.
Antimicrobial Agents and Chemotherapy|October 30, 1999
Pharmacokinetics of dapsone administered daily and weekly in human immunodeficiency virus-infected childrenM Mirochnick, E Cooper, K McIntosh, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 6, 2003
Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 monthsAvinash K Shetty, Hoosen M Coovadia, Mark M Mirochnick, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
AIDS (London, England)|April 10, 1999
A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006)P Musoke, L A Guay, D Bagenda, et al.
HIV Medicine|March 28, 2008
Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokineticsE V Capparelli, F Aweeka, J Hitti, et al.
Lancet (London, England)|September 15, 1999
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trialL A Guay, P Musoke, T Fleming, et al.
Antimicrobial Agents and Chemotherapy|October 30, 1999
Pharmacokinetics of dapsone administered daily and weekly in human immunodeficiency virus-infected childrenM Mirochnick, E Cooper, K McIntosh, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 6, 2003
Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 monthsAvinash K Shetty, Hoosen M Coovadia, Mark M Mirochnick, et al.
Pageof 4